Feasibility study of alternate-day S-1 as adjuvant chemotherapy for head and neck cancer.

Abstract

AIM:

This study analyzed the safety and feasibility of alternate-day S-1, a mixture of tegafur, dehydroxypyrimidine and potassium oxonate, as adjuvant chemotherapy for head and neck cancers.

PATIENTS AND METHODS:

Patients with head and neck squamous cell carcinoma (HNSCC) who underwent primary treatment received alternate-day S-1 (80 mg/day for 1 year). The primary end-point was treatment completion rate. The secondary end-point was adverse events. Three-year overall survival (OS) and disease-free survival (DFS) were calculated using the Kaplan-Meier method.

RESULTS:

One-year completion rate was 65.6%. Out of 26 patients, 19.0% had grade III adverse events. All adverse reactions were tolerable and reversible. Three-year OS and DFS were 74.8% and 57.3%, respectively.

CONCLUSION:

S-1 therapy is an effective adjuvant treatment for head and neck cancer patients with relatively mild side-effects and does not adversely affect quality of life. A phase I/II study is warranted to investigate the appropriate dose for an alternate-day S-1 regimen.

• Authors: Yorihisa Moro, Yasunao Kogashiwa, Dai Sato, Yoshifumi Matsumoto, Takehiro Nakamura, Koichi Yamauchi, Hiroyuki Sakurai, Naoyuki Kohno
• Journal: Anticancer research (Anticancer Res) Vol. 35 Issue 2 Pg. 977-81 (Feb 2015) ISSN: 1791-7530 [Electronic] Greece
• PMID: 25667484 (Publication Type: Journal Article)
• Copyright: Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Chemical References

• Drug Combinations
• S 1 (combination)
• Tegafur
• Oxonic Acid

Topics

• Adult
• Aged
• Aged, 80 and over
• Chemotherapy, Adjuvant
• Drug Combinations
• Feasibility Studies
• Female
• Head and Neck Neoplasms (drug therapy)
• Humans
• Male
• Middle Aged
• Oxonic Acid (therapeutic use)
• Tegafur (therapeutic use)